socalTECH

NOVEMBER 9, 2020

San Diego-based Arcturus Therapeutics has received up to $220M in additional financial commitments from the country of Singapore, after receiving positive Phase 1/2 study results on one of its compounds. READ MORE>>.

Arcturus 113

Arcturus Study San Diego Funding 113

socalTECH

JANUARY 27, 2016

San Diego-based biopharmaceuticals developer Halozyme Therapeutics said yesterday that it has raised $150M in royalty-backed, debt financing. According to the company, the funding will go towards a Phase 3 cancer study in cancer patients. The financing came from Pharmakon Advisors and Athyrium Capital Management.

Funding 100

Funding San Diego Study Capital 100

socalTECH

MARCH 28, 2019

San Diego-based biotech startup Biolinq , which is developing wireless-enabled biosensor patches for continuous monitoring of biomarkers, has raised $4.75M additional Series A funding, the company said this morning. The funding came from JDRF T1D Fund, Aphelion Capital and LifeSci Venture Partners.

Marketing 168

Marketing San Diego Venture Capital Study 168

socalTECH

JULY 28, 2021

San Diego-based immunology startup Aristea Therapeutics says it has raised $63M in a Series B financing round, which was led by Fidelity Management & Research Company, LLC, along with Novo Holdings A/S, plus Arena Pharmaceuticals and funds managed by Tekla Capital Management, LLC. Mackay, Ph.D.

San Diego 100

San Diego Study Research Capital 100

socalTECH

OCTOBER 23, 2019

San Diego-based Intrepida Bio , a biopharmaceuticals startup focused on developing medicines that modulate the innate immune system to fight cancer and other diseases, has raised $9.5M in a funding round, according to the company. The funding came from Sofinnova Investments and Canaan. Martin, Ph.D.,

San Diego 100

San Diego Study Funding Invest 100

socalTECH

OCTOBER 1, 2018

San Diego-based VelosBio , a biotech startup developing novel antibody-drug conjugates to treat hematological cancers and solid tumours, has raised $58M in a funding round. The Series A funding was led by Arix Bioscience, and also included Pappas Ventures, Chiesi Ventures, Takeda Ventures, and Decheng Capital.

San Diego 113

San Diego Study Funding Capital 113

socalTECH

APRIL 1, 2020

San Diego-based Aspen Neuroscience , a biotechnology company developing treatments for Parkinson disease, said it has raised $70M in a Series A funding round. The funding was led by OrbiMed, and also included ARCH Venture Partners, Frazier Healthcare Partners, Domain Associates, Section 32, and Sam Altman.

San Diego 113

San Diego Screening Study Course 113

socalTECH

NOVEMBER 7, 2018

San Diego-based Mirium Pharmaceuticals , which is developing treatments for rare liver diseases, announced on Wednesday morning that it has raised $120M in a Series A funding round. The company says it recently had a successful Phase 2b study. READ MORE>>.

San Diego 147

San Diego Study Capital Funding 147

Xconomy

DECEMBER 18, 2019

More than 250 miles above the Earth’s surface aboard the International Space Station, a first-in-kind study of neurodegenerative disease is expected to reveal never-before-seen cell interactions.

Research 90

Research San Diego Study Funding 90

socalTECH

MAY 9, 2018

San Diego-based Escient Pharmaceuticals announced Wednesday morning that it has raised $40M in a Series A funding, to develop drugs to treat neuro-immuno-inflammatory and autoreactive diseases. The funding came from The Column Group and 5AM Ventures, along with Osage University Partners. READ MORE>>.

San Diego 100

San Diego Study Funding Develop 100

Xconomy

SEPTEMBER 15, 2016

San Diego’s innovation clusters continued to grow in 2015, as local startups, funding deals, and job growth extended an economic growth spurt that began in 2013. The Connect Innovation Report found that 405 software, technology, and life sciences startups were created last year in San Diego County.

San Diego 40

San Diego Report High Tech Study 40

socalTECH

JULY 24, 2017

San Diego-based eFFECTOR Therapeutics , a developer of treatments for cancer, has raised $38.6M in a Series C funding round, the company announced this morning. The funding was led by Pfizer Venture Investments (PVI), and also included Alexandria Venture Investments, along with U.S. in total funding.

Study 113

Study San Diego Invest Funding 113

Xconomy

OCTOBER 1, 2018

VelosBio joined Johnson & Johnson’s JLABS @ San Diego incubator in January. The company is developing antibody drug conjugates, a class of cancer drug that links antibodies to potent cancer-fighting toxins. The new VelosBio cash is earmarked for completing the work needed to proceed into human studies.

San Diego 91

San Diego Incubator Class Study 91

Xconomy

APRIL 22, 2019

The race to bring CAR-T cell therapy to multiple myeloma, a persistent and deadly cancer of the bone marrow, continued on Monday with a fresh round of funding for Poseida Therapeutics. Poseida plans to begin administering its experimental treatment P-BCMA-101 to patients in a Phase 2 study later this year.

San Diego 83

San Diego Study Funding Invest 83

socalTECH

JANUARY 5, 2016

San Diego-based Halozyme Therapeutics , the publicly held cancer therapeutics developer, has entered into a $150M credit agreement, the company said this morning. The debt funding comes from Pharmakon Advisors and Athyrium Capital Management. READ MORE>>.

Study 100

Study San Diego Capital Funding 100

socalTECH

SEPTEMBER 12, 2018

San Diego-based Epic Sciences , which is developing technology around personalization of cancer treatment and management, has raised $52M more in a Series E funding, the company's lead investor said this morning. Epic has now raised more than $137.5M RUSNANO, and VI Ventures. READ MORE>>.

Artificial Inteligence 100

Artificial Inteligence San Diego Study Invest 100

socalTECH

MAY 7, 2010

Five, Southern California firms are among companies who are splitting up $62M in government funding for the research, development, and demonstration of concentrating solar power systems, according to an announcement by the U.S. for building a solar power tower plant design; San Diego-based General Atomics getting up to $2.1M

Canoga Park 186

Canoga Park Research Southern California Chatsworth 186

socalTECH

MAY 11, 2015

San Diego-based Ligand Pharmaceuticals announced this morning that it has acquired more than 15 different programs from Selexis SA , for $4M in cash. Ligand--which develops a range of pharmaceuticals--said that it acquired a number of programs in various stages of development, ranging from preclinical through Phase 3 studies.

San Diego 100

San Diego Study Funding Develop 100

TechCrunch LA

SEPTEMBER 25, 2020

This probably isn’t news to developers, but it was news to me when I found out many tech companies still use slave-master language. A new poll from the UC Berkeley Institute of Governmental Studies found that it’s going to be a close election. Human Capital will soon be available as a weekly newsletter. You can sign up here.

Capital 316

Capital Los Angeles News San Diego 316

socalTECH

JULY 7, 2015

San Diego-based oncology products developer Ignyta said late Monday that it is in a clinical trial collaboration with the University of California, San Francisco (UCSF). Ignysta said that UCSF will study its compound, entrectinib, in a proof-of-concept clinical trial in cancer patients with metastatic melanoma.

San Diego 100

San Diego Study Funding Product 100

socalTECH

DECEMBER 6, 2012

San Diego-based Avelas Biosciences has raised $7.65M in a Series A funding round, which it says will go towards clinical studies for its technology for real-time tumor visualization. The funding came from Avalon Ventures. The firm's CEO is currently Jay Lichter, who is also a Managing Director at Avalon Ventures.

Avalon 138

Avalon San Diego Study Technology 138

socalTECH

MAY 25, 2012

San Diego-based biopharmaceuticals firm Sangart has raised $50M in a Series G funding round, the company announced Thursday, bringing its total venture funds raised to $280M. The firm said the funding will go towards advancing development of its medicines, which are currently in Phase 2b studies.

San Diego 133

San Diego Study Funding Develop 133

Xconomy

FEBRUARY 15, 2017

Liver disease is challenging for doctors because it can develop without symptoms, making diagnosis difficult without removing cells for examination. For these reasons, fatty liver disease is often called a “silent disease,” says Ariel Feldstein, a gastroenterologist at the University of California San Diego.

UCSD 64

UCSD Press San Diego Class 64

Xconomy

APRIL 11, 2017

As part of the financing, Kalamazoo-based Octeta Therapeutics has been rechristened Cirius Therapeutics, and three San Diego-based biotech executives are stepping into key executive roles. All three were former Laguna Pharmaceuticals executives who spent the past 16 months scouting for Frazier as entrepreneurs-in-residence.

Study 55

Study San Diego Entrepreneur Venture Capital 55

socalTECH

MARCH 12, 2012

San Diego-based HemaQuest Pharmaceuticals said today that it has raised $13M in a Series B funding. The new funds will go towards a Phase 2b clinical study to apply its compound to patients with sickle cell disease. READ MORE>>.

San Diego 124

San Diego Study Funding Develop 124

Xconomy

NOVEMBER 3, 2017

Klotho Therapeutics , a virtual biotech developing a kidney disease treatment based on its proprietary engineered version of the human klotho enzyme, said Thursday it has raised $10 million in Series A financing from San Diego’s Thynk Capital. Studies in mice have.

San Diego 85

San Diego Study Capital Technology 85

Xconomy

APRIL 18, 2018

John Dobak, a life sciences serial entrepreneur in San Diego, said a new startup he’s leading has raised $2.66 The biotech, 10xBio, announced earlier this month that the FDA had approved its application to begin clinical trials in Phase 1b/2a studies testing the unnamed injectable drug.

San Diego 72

San Diego Study Entrepreneur Startup 72

socalTECH

JANUARY 4, 2012

San Diego-based Elevation Pharmaceuticals , which is developing treatment for patients with chronic obstructive pulmonary disease (COPD), said this morning that it has closed on a $30M, Series B funding round. joins the company's board with the funding. Novo's Heath Lukatch , Ph.D., READ MORE>>.

San Diego 133

San Diego Study Activity Funding 133

socalTECH

NOVEMBER 11, 2010

San Diego-based Aires Pharmaceuticals , a developer of treatments for pulmonary arterial hypertension, said this morning that it has raised $20M in a Series B funding round. MPM's Dr. William Greene joins the board as part of the funding. The deal with Novartis could be worth as much as $250M.

San Diego 154

San Diego Venture Capital Study Capital 154

Xconomy

SEPTEMBER 27, 2016

[ Note: The headline has been corrected to better describe the company’s type of funding. Fortis Therapeutics, a new San Diego biotech, has raised $18 million in initial funding to develop drugs for hard-to-treat prostate and bone marrow cancers. 9/27/16, 2:09 p.m.

Avalon 40

Avalon Funding Startup San Diego 40

socalTECH

APRIL 15, 2019

San Diego-based Wheels (www.takewheels.com) was co-founded by Jon and Josh Viner, who were the co-founders of Wag, where they raised nearly $400M in venture capital. Wheels currently operates in Los Angeles and San Diego. Josh Viner: Wheels is live in Los Angeles and San Diego. What is Wheels?

San Diego 113

San Diego Startup Study Los Angeles 113

socalTECH

JUNE 23, 2010

San Diego-based Nereus Pharmaceuticals , a firm developing drugs for the treatment of lung cancer, said Tuesday that it has raised another $20M in funding and commitments from its venture backers.

San Diego 140

San Diego Venture Capital Study Funding 140

socalTECH

AUGUST 5, 2010

Carslbad-based Life Technologies , a developer of genomic analysis technology, and the University of California at San Diego 's Moores Cancer Center, said this morning that the two are collaborating on a research effort.

UCSD 145

UCSD Technology San Diego Study 145

socalTECH

AUGUST 30, 2010

San Diego-based Otonomy , a biopharmaceuticals firm developing products to treat disorders of the inner and middle ear, announced today that it has raised $38.5M The firm said the new fundings will go to support its programs through clinical studies. in a Series B financing.

Avalon 150

Avalon San Diego Venture Capital Study 150

socalTECH

FEBRUARY 19, 2016

San Diego-based eFFECTOR Therapeutics , which is developing gene translation technology to help in the treatment of cancer, has boosted its Series B funding to $56M, the company said Friday. The company--which raised $40M in the round back in December--said the new funding came from Sectoral Asset Management.

San Diego 100

San Diego Funding Capital Help 100

Xconomy

DECEMBER 7, 2017

Metacrine , a biotech developing new drugs for treating chronic liver diseases and related metabolic diseases and disorders, said today it has raised $22 million in a Series B financing led by New Enterprise Associates, a new investor. Initial studies should be completed by the end of the year, the San Diego-based company said.

San Diego 49

San Diego Study Develop Development 49

socalTECH

JUNE 11, 2010

San Diego-based Otonomy , which is developing treatments for Meniere's disease, said today that it has raised $10M in a Series A financing round. The round came from Avalon Ventures. Otonomy is headed by Jay Lichter, who is also a managing director at Avalon Ventures. READ MORE>>.

Avalon 113

Avalon San Diego Study Capital 113